Home Page
Realizing the promise of glycobiology

Programs Funded by the National Cancer Institute

A strong body of evidence has demonstrated that targeting specific glycan structures can inhibit the progression of various tumors. To unlock this potential, Zacharon created breakthrough assay technologies integrating cell-based high-throughput screening with highly sensitive glycan structural analysis. This technology breakthrough has enabled the development of an entire new class of anti-cancer therapeutics targeting glycans.

Zacharon has several drug development programs funded by the National Cancer Institute targeting heparan sulfate, gangliosides, and other glycan structures strongly implicated in tumor progression. Proof of concept has been demonstrated using in vivo cancer models, and preclinical development activities are being conducted to enable this innovative class of anti-cancer therapies.

Please visit www.projectreporter.nih.gov for more information regarding Zacharon programs funded by the National Cancer Institute.